Ridaforolimus in Treating Patients With Recurrent Metastatic and/or Locally Advanced Endometrial Cancer

DISEASE CHARACTERISTICS: * Histologically confirmed endometrial cancer, including any 1 of the following subtypes: * Adenocarcinoma * Papillary serous * Papillary * Villoglandular * Mucinous * Clear cell * Endometrioid * Adenosquamous carcinoma * Recurrent or metastatic and/or locally advanced disease * Incurable disease by standard therapies * Clinically and/or radiologically documented disease within the past 28 days (35 days if negative), defined as ≥ 1 unidimensionally measurable disease site meeting 1 of the following criteria: * At least 20 mm by x-ray or physical exam * At least 10 mm by spiral CT scan * At least 20 mm by non-spiral CT scan * Available tumor tissue (paraffin block or unstained slides) from primary tumor * No uterine sarcoma (leiomyosarcoma), mixed müllerian tumor (MMT), and/or adenosarcoma * No known brain metastases * Clinical suspicion of CNS involvement requires a head CT scan PATIENT CHARACTERISTICS: * ECOG performance status 0-2 * Life expectancy ≥ 12 weeks * Granulocyte count ≥ 1,500/mm³ * Platelet count ≥ 100,000/mm³ * Bilirubin ≤ upper limit of normal (ULN) * ALT and AST ≤ 2.5 times ULN * Creatinine ≤ 1.25 times ULN OR creatinine clearance ≥ 50 mL/min * Fasting serum cholesterol ≤ 9.0 mmol/L * Fasting triglycerides ≤ 4.56 mmol/L * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * Accessible for treatment and follow up (e.g., 1 ½ hours driving distance…